Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (RA-BioStop)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

biological DMARDs may be stopped in Rheumatoid Arthritis (RA) patients treated with a combination of synthetic DMARD plus bDMARDs which are in persistent clinical remission. The research question of this study is, whether musculoskeletal sonography is a useful biomarker predicting a disease flare after cessation of bDMARD therapy.

Condition or disease	Intervention/treatment	Phase
Rheumatoid Arthritis	Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)	Phase 4

Detailed Description:

Rheumatoid arthritis (RA) is the most common inflammatory joint disease. It is usually treated with synthetic and biologic disease modifying antirheumatic drugs (DMARDs). Up to 35% of patients can achieve clinical remission by the combination these therapies; however, there is considerable uncertainty regarding the management of patients once this clinical state is achieved. The discontinuation of biological agents in patients with persistent clinical remission may be beneficial for the patients and the health care system reducing the risks of long term adverse events and saving costs, respectively. Up to 60% of patients were reported to flare after cessation of anti-tumor necrosis factor alpha (TNF alpha) therapy despite continuation of synthetic DMARDs and up to now there exist no validated biomarkers that predict which patients will suffer a flare and which patients will remain in remission.

Sonography is more and more used as a biomarker in RA. Subclinical inflammation was previously associated with an increased risk for short term clinical relapse and structural deterioration.

The hypothesis of this prospective study is that ultrasound verified subclinical inflammation at the time of bDMARD withdrawal predicts a disease flare at week 16. The investigators plan to recruit RA-patients with persistent clinical remission according to SDAI and no current corticosteroid therapy. At baseline, bDMARD is stopped, synthetic DMARDs are continued. Patients undergo 9 study visits within 52 weeks. Ultrasound examinations of 14 joints as well as clinical and laboratory assessments with calculation of SDAI scores are performed at each visit. Patients are considered to have a disease flare if disease status changes from remission to active disease according to clinical scores. Patients with a flare of the disease are excluded from the active phase of the study and are treated according to current guidelines.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	110 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis
Study Start Date :	June 2012
Estimated Primary Completion Date :	July 2018
Estimated Study Completion Date :	September 2018

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: single arm ( bDMARD withdrawal ); single arm (bDMARD withdrawal)	Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants; Other Names: Enbrel; Humira; Remicade; Cimzia; Simponi; Roactemra; Orencia

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. PD-signals predict relapse at week 16 [ Time Frame: 16 weeks ]
   Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 16.

Secondary Outcome Measures :

1. PD-signals predict relapse at week 24 [ Time Frame: 24 weeks ]
   Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 24
2. PD-signals predict relapse at week 52 [ Time Frame: 52 weeks ]
   Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 52
3. PD-scores at time of relapse [ Time Frame: 24 weeks ]
   RA-patients have higher PD-scores at time of a clinical flare compared to patients with maintained clinical remission
4. Increment of PD-scores precede flare [ Time Frame: 52 weeks ]
   An increment of PD-scores at follow-up compared to baseline visits precedes a clinical flare
5. PD scores better predict a relapse than residual swollen joints [ Time Frame: 16, 24, 52 weeks ]
   PD scores better predict a relapse at week 16, 24 and 52 than the presence of residual swollen joints
6. PD score at baseline correlates with relapse risk [ Time Frame: 52 weeks ]
   The higher the PD score at baseline, the more likely is a relapse at weeks 16, 24 and/or 52
7. 7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive [ Time Frame: 16, 24, 52 weeks ]
   7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive
8. 8. Blood biomarkers predict the time to flare after bDMARD withdrawal
   8. Blood biomarkers predict the time to flare after bDMARD withdrawal
9. 9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment
   9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment
10. PD-scores and blood biomarkers at baseline predict radiographic progression at week 52 [ Time Frame: 52 ]
    PD-scores and blood biomarkers at baseline predict radiographic progression at week 52

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Male or female patient ≥18 years and <90 years of age
• Classification of RA according to the ACR/EULAR 2010 criteria
• Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)
• Written informed consent
• Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor
• No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks
• Stable dose of NSAIDs for at least 1 week

Exclusion Criteria:

• • Current treatment with any investigational drug
• Current administration interval of the anti-TNF-alpha agent of >11 weeks
• Complete destruction of any joint to be investigated by sonography
• Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules
• Initial arthritis manifestations before the age of 17 years
• Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography
• Current severe medical illness requiring hospitalization
• Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent
• Pregnancy or lactation
• Inability of the patient to follow the protocol
• Current treatment with Rituximab (MabThera®)

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Christian Dejaco, MD, PhD	+43-316-80595	christian.dejaco@gmx.net
Contact: Josef Hermann, MD	+43-316-80248	josef.hermann@medunigraz.at

Locations

Austria
Medical University Graz	Recruiting
Graz, Austria, 8036
Contact: Christian Dejaco, MD, PhD +43-316-80595 christian.dejaco@gmx.net
Principal Investigator: Christian Dejaco, MD, PhD

Sponsors and Collaborators

Medical University of Graz

Investigators

Principal Investigator:	Christian Dejaco, MD, PhD	Medical University of Graz

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Dejaco Christian, MD, PD, Dr., Medical University of Graz
ClinicalTrials.gov Identifier:	NCT01602302 History of Changes
Other Study ID Numbers:	2011-5; V2; 2011-005204-15 ( EudraCT Number )
First Posted:	May 18, 2012
Last Update Posted:	March 30, 2018
Last Verified:	March 2018

Keywords provided by Dejaco Christian, MD, Medical University of Graz:

rheumatoid arthritis; ultrasound; remission; biological DMARD

Additional relevant MeSH terms:

Arthritis; Arthritis, Rheumatoid; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Adalimumab; Etanercept; Infliximab; Abatacept; Certolizumab Pegol	Anti-Inflammatory Agents; Antirheumatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents